Search
Verubecestat
go.drugbank.com/drugs/DB12285InvestigationalIn the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.
Subasumstat
go.drugbank.com/drugs/DB16406InvestigationalSubasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced … or Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)).
Silanol
go.drugbank.com/drugs/DB11343ApprovedSilanol is an FDA-approved food contact substance that is commonly used in organosilicon chemistry and silicate mineralogy.
Zofin
go.drugbank.com/drugs/DB16519InvestigationalZofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the
Sesame oil
go.drugbank.com/drugs/DB11172ApprovedNutraceuticalSesame oil is a commonly used vegetable oil in Asia and flavoring enhancer in various culinary practices. … Sesame oil is considered an indirect additive used in food cotact substances by the FDA.
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalIt is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary
R411
go.drugbank.com/drugs/DB05468ExperimentalR411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. … It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7.
SYN-101
go.drugbank.com/drugs/DB05958ExperimentalSYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility … of the GI tract is severely impaired.
Idraparinux
go.drugbank.com/drugs/DB06406InvestigationalIdraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.